APOL1 Counseling Training Program for Genetic Predisposition to Disease

Phase-Based Progress Estimates
Genetic Predisposition to Disease+5 More
APOL1 Counseling Training Program - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will test whether a chatbot can help African American living kidney donors make informed decisions about their health.

Eligible Conditions
  • Genetic Predisposition to Disease
  • Chronic Kidney Disease (CKD)
  • Predisposition, Genetic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Genetic Predisposition to Disease

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Post-intervention, up to 5 years

Approximately Day 14
Genetic variation knowledge assessment index (GKAI)
Health Professionals Beliefs about Race (HPBR) scale
Practical Knowledge and Self-Efficacy in Genetic Counseling
Racial attributes in clinical evaluation (RACE) scale
Approximately Month 12
Acceptability of Intervention Measure (AIM)
Feasibility of Intervention Measure (FIM)
Intervention Appropriateness Measure (IAM)
Approximately Month 25
Barriers and Facilitators to APOL1 testing Implementation
Approximately Month 36
Clinical Sustainability Assessment Tool (CSAT)
Year 5
Number and quality of prescribed Post-Test counseling practices
Number and quality of prescribed Pre-Test counseling practices

Trial Safety

Safety Progress

1 of 3

Other trials for Genetic Predisposition to Disease

Trial Design

1 Treatment Group

Counseling Training Program
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: APOL1 Counseling Training Program · No Placebo Group · N/A

Counseling Training Program
Experimental Group · 1 Intervention: APOL1 Counseling Training Program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: post-intervention, up to 5 years

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,525 Total Patients Enrolled
2 Trials studying Genetic Predisposition to Disease
282 Patients Enrolled for Genetic Predisposition to Disease
Georgetown UniversityOTHER
317 Previous Clinical Trials
120,465 Total Patients Enrolled
1 Trials studying Genetic Predisposition to Disease
261 Patients Enrolled for Genetic Predisposition to Disease
Elisa J Gordon, PhD, MPHPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials
8 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The individual is not cognitively impaired.
Adults are individuals who are 18 years old and older.
will be offered the intervention Transplant nephrologists who are evaluating live kidney donor candidates will be offered the intervention.
The person is not vision impaired.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.